Verteporfin reversed these effects...MMRN1 acts as a tumor suppressor in TC by activating the Hippo pathway and modulating oxidative stress and ferroptosis. These findings highlight MMRN1 as a potential therapeutic target for TC treatment.

Despite the documented anti-inflammatory effects of Psoralen (PSO), the exact mechanism by which it confers protection against septic ALI remains poorly understood...Moreover, PSO enhanced intestinal tight junction protein expression. Nonetheless, these protective effects were abolished by the AhR inhibitor CH-223191.

P2, N=24, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2029 --> Mar 2031 | Trial primary completion date: Dec 2029 --> Mar 2028 | Recruiting --> Active, not recruiting

In vivo fluorescence imaging demonstrated enhanced tumor accumulation and prolonged retention of Ce6-RWYD compared with the talaporfin sodium (NPe6)...Combination with anti-PD-1 further enhanced antitumor efficacy, accompanied by increased intratumoral CD8⁺ T-cell infiltration and reduced Gr-1⁺ myeloid cells. Collectively, these findings demonstrate that Ce6-RWYD-mediated PDT sensitizes MSS colorectal cancer to PD-1 blockade.

Mechanistic investigations demonstrated that light-triggered reactive oxygen species generation activates the caspase-3/GSDME-mediated pyroptosis pathway. This study demonstrated a rationally designed, targeted nanoplatform that utilizes a multifunctional Ru(II)-based photosensitizer and induces pyroptosis, providing a viable approach to improve the efficacy of tumor photodynamic therapy.

Increased NDUFB3 expression in RANBP1-overexpressing cells was reversed by YAP1 inhibitor verteporfin treatment or knocking down YAP1. RANBP1 enhances a more invasive microenvironment of OSCC.

P2, N=112, Not yet recruiting, Therakos LLC

P1, N=130, Suspended, Fox Chase Cancer Center | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027

The significantly differentially expressed genes (DEGs) from the Gene Expression Omnibus (GEO) database, which discriminate AGS and MKN45 cells in the presence of DMSO and verteporfin (a chemotherapy reagent), are determined...MKN45 was highlighted as more invasive cancer cell relative to AGS cells. PLOD2 was pointed out as a suitable target in the chemotherapy of gastric cancer.

This study identified a novel CAF-exosome-YAP-USP8-HER2 signaling axis that drives trastuzumab insensitivity in HER2-positive breast cancer. Intervening in this pathway may represent a potential treatment approach to counteract microenvironment-induced chemoresistance.

P1/2, N=19, Completed, Roswell Park Cancer Institute | Terminated --> Completed

P1/2, N=12, Not yet recruiting, Odense University Hospital